Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Revised ciprofloxacin dosing in renal impairment bioequivalence study
NL-OMON21894Recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Aug 2020
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Open-label trial of ciprofloxacin in bacterial disease (2 arms), sponsored by Amsterdam University Medical Center. Primary endpoint: Bioequivalence of AUC0-24. Started Aug 2020; status: recruiting.
02
Drugs
ciprofloxacin
03
Conditions
bacterial disease
Beyond the preview
Go deeper on NL-OMON21894.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON21894.